¶ NLRP3 Protein (NLR Family Pyrin Domain Containing 3)
Nlrp3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NLRP3 (NLR Family Pyrin Domain Containing 3) is a key component of the inflammasome complex. It is also known as NALP3 or cryopyrin, and plays a central role in innate immunity and inflammatory responses. NLRP3 is implicated in the pathogenesis of multiple neurodegenerative diseases through its role in neuroinflammation.
| Property |
Value |
| Protein Name |
NLRP3 / NALP3 / Cryopyrin |
| Gene Symbol |
NLRP3 |
| UniProt ID |
Q96P20 |
| Molecular Weight |
118 kDa |
| Structure |
PYD, NACHT, LRR domains |
| Expression |
Immune cells, neurons, astrocytes, microglia |
| Subcellular Localization |
Cytoplasm |
NLRP3 is a pattern recognition receptor:
- Inflammasome Assembly: Forms multi-protein complex with ASC and caspase-1
- Cytokine Activation: Converts pro-IL-1β and pro-IL-18 to active forms
- Pathogen Detection: Recognizes PAMPs and DAMPs
- Pyroptosis: Induces inflammatory cell death
- Innate Immunity: Initiates inflammatory responses
NLRP3 activation occurs through multiple pathways:
- Canonical Inflammasome: ASC recruitment and caspase-1 activation
- K+ Efflux: Low intracellular potassium triggers activation
- Mitochondrial ROS: ROS production activates NLRP3
- Lysosomal Damage: Cathepsin B release activates NLRP3
- NEK7 Interaction: NEK7 is required for NLRP3 activation
- NLRP3 inflammasome activated in AD brain
- Drives neuroinflammation
- Contributes to Aβ pathology
- NLRP3 in microglia in PD brain
- Contributes to dopaminergic neuron loss
- Therapeutic target
- Activated in ALS models
- Motor neuron inflammation
- Therapeutic potential
- Central role in demyelination
- Microglial activation
- Therapeutic target
- NLRP3 gain-of-function mutations
- Autoinflammatory disease
- IL-1 blocking therapy effective
- NLRP3 inhibitors: MCC940, Dapansutrile
- IL-1 blocking therapy: Anakinra, Canakinumab
- Anti-inflammatory agents: Broad-spectrum approaches
- Microglial modulation: Target neuroinflammation
- NLRP3 knockout mice: Protected from neurodegeneration
- CAPS knockin models: Inflammatory phenotypes
- AD models: NLRP3 deletion improves cognition
- PD models: Reduced neuroinflammation
- NLRP3 inhibitor development
- Inflammasome biomarkers
- Cell-type specific targeting
- Clinical translation
The NLRP3 inflammasome is one of the most well-characterized inflammasomes:
- Priming signal (Signal 1): NF-κB activation leads to NLRP3 and pro-IL-1β transcription
- Activation signal (Signal 2): Various triggers cause:
- K+ efflux through ion channels
- ROS production from mitochondria
- Lysosomal rupture (particulate matter)
- ATP binding to P2X7 receptors
- Assembly: NLRP3 recruits ASC adaptor protein, which then recruits pro-caspase-1
- Activation: Caspase-1 auto-cleavage activates the inflammasome complex
Key animal models for studying NLRP3:
- Nlrp3-/- mice: Lack NLRP3 function, resistant to inflammatory diseases
- Nlrp3 gain-of-function mice: Show spontaneous inflammation and premature aging
- Transgenic NLRP3 models: Express human NLRP3 mutations
- AD/PD models: NLRP3 deficiency reduces pathology in APP/PS1 and α-syn models
| Drug/Compound |
Mechanism |
Status |
| MCC950 |
Direct NLRP3 inhibitor |
Phase II (COVID-19, MS) |
| Dapansutrile (OLT1177) |
NLRP3 inhibitor |
Phase I/II |
| Tranilast |
NLRP3 inhibition |
Approved (Japan, allergies) |
| Anti-IL-1β antibodies |
Downstream blockade |
Approved (IL-1Ra) |
| Caspase-1 inhibitors |
Block inflammasome |
Research |
The study of Nlrp3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.